S leep-disordered breathing (SDB) is being increasingly recognized as a vascular risk factor implicated in the whole spectrum of vascular diseases ranging from coronary heart disease and congestive cardiac failure to hypertension and stroke. It is important not only with respect to the magnitude of risk it raises, but also as an effectively treatable risk factor. In the instance of cerebrovascular disease, the evidence has moved from the initial dilemma of SDB as cause or consequence of stroke to that of a definitive risk requiring appropriate means of therapy. In the following review we will be discussing the weight of evidence linking SDB with cerebrovascular disease, and the issues pertaining to evidences generated by treatment trials.
What is Sleep-disordered breathing?
In the broadest term SDB includes snoring, obstructive sleep apnea and central apnea. However, in sleep medicine parlance, SDB is mainly considered as SnoringUpper airway resistance syndrome-Obstructive sleep apnea spectrum.
Sleep apnea refers to temporary respiratory pauses during sleep. To be of significance it should be 10 seconds or more. Sleep apnea can be obstructive, central or mixed. In obstructive sleep apnea there is cessation of airflow through nose or mouth, but with continuing respiratory effort as evidenced by diaphragmatic and intercostals muscle activities. In central apnea, there is no respiratory effort at all. Mixed apnea begins as central apnea with cessation of airflow and respiratory effort, but appears as obstructive apnea towards the end with appearance of respiratory effort, while nasal and mouth airflow show continuing restriction. 1 Sleep hypopnea is defined as 30% or more airflow limitation associated with 4% or more oxygen desaturation. 2 Sleep apnea and hypopnea are combined together in an index called Apnea-hypopnea or Respiratory disturbance index (AHI or RDI) defined as number of apneas or hypopnea per hour of sleep. Normal AHI is less than 5.
Obstructive sleep apnea syndrome (OSAS) refers to the polysomnography demonstrated OSA together with the clinical consequences of impaired sleepiness. The diagnostic criteria for OSAS devised by task force of the American Academy of Sleep Medicine is given in table 1 3 In Upper airway resistance syndrome there is no airflow limitation significant enough to cause apneahypopnea and oxygen desaturation, but flow limitation causes recurrent arousals and resultant sleep fragmentation. The UARS cannot be identified by usual PSG recording of respiration using oronasal themistor, but requires nasal pressure monitoring using nasal cannula or better still, by the gold standard, intraoesophageal balloon manometery. Patients with UARS exhibit all the clinical manifestation and consequences of obstructive sleep apnea. 4 
Evolutionary biology
Sleep-disordered breathing is itself a consequence of features unique to upper airway system of humans. In humans, in contrast to other animals, the larynx is much descended, has a narrow distensible supralaryngeal vocal tract, has no epiglottic-soft palate lock-up (allowing a oropharyngeal tongue) and has an acute cranial base angulation all allowing the already compromised upper airway to the mercy of pharyngeal dilator muscle tone. In sleep, there is normal reduction in the pharyngeal dilator tone. This, superimposed on already narrowed and/or compliant pharynx causes upper airway obstruction. T M Davidson who put forward this debate, persuasively argues that sleep apnea is thus the evolutionary price that humans pay for their ability for speech.
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OSA and Cerebrovascular diseasesPathogenetic mechanisms
The common denominator in the pathogenetic mechanisms described is the intermittent hypoxemia seen in patients with OSA. Repeated intermittent hypoxia is shown to cause diurnal elevation of BP in rats. The resting sympathetic activity in patients with OSA is found to be elevated. There is evidence of endothelial dysfunction, 6 enhanced release of oxygen free radicals, 7, 8 increased expression of adhesion molecules 8 and inflammatory mediators, [9] [10] [11] [12] increased lipid peroxidation 7 and insulin resistance 12, 13 in patients with OSA.. There are also studies showing increased platelet aggregation, increased fibrinogen levels and prothrombotic state in patients with OSA. Most of these-the endothelial dysfunction, the oxidative stress, the plasma NO level, insulin resistance and baseline sympathetic activity-have been shown to improve after treatment with CPAP.
Vascular consequences
Sleep-disordered breathing is thought to mediate various vascular consequences both by directly acting on the pathogenetic mechanisms and also by indirectly Table 2 Obstructive sleep apnea (OSA): Polysomnography demonstrated obstructive sleep apnea with apnea-hypopnea index more than 5.
Obstructive sleep apnea syndrome (OSAS):
OSA with clinical manifestations of impaired night-time sleep (see Table 1 ).
Upper airway resistance syndrome (UARS):
• A condition characterized by airflow limitation causing recurrent arousals and sleep fragmentation, but not enough to cause sleep apnea or hypopnea.
• Demonstration requires nasal pressure monitoring using nasal cannula or intraoesophageal balloon manometry.
• Usual polysomnography recording shows recurrent flow-limitation and arousal, but no sleep apnea/hypopnea.
• Associated with all clinical manifestation and consequences of OSA modulating known risk factors.
In the context of cerebrovascular diseases, the significance of SDB was first recognized when it was found that there was disproportionately high prevalence of SDB in patients with stroke compared with matched normal population. While the community prevalence of OSAS (OSA + EDS with AHI > 5) in the Wisconsin study by Young et al was 4% in men and 2% in females, the prevalence of OSA (AHI > 10) in stroke patients varies from 44% to as high as 96% depending on the setting of the study (6 weeks old stroke versus 2 weeks old stroke) ( Table 3) 17-23 . With the observation of decreasing prevalence of OSA with increase in duration from stroke, its occurrence was initially attributed to be a consequence of stroke. However, subsequent studies have clearly shown that OSA is, in addition, as an independent risk factor for stroke too.
OSA as an independent risk factor for stroke
Yaggi et al in an observational cohort study involving 1022 patients with 4 years follow up has shown that hazards ratio (HR) of OSA for stroke or all cause mortality was 2.24 (1.3-3.86, 95% CI), well above that for conventional risk factors like hypertension (1.48), diabetes (1.56), hyperlipidemia (1.04) and smoking (1.23) . When the hazards ratio was adjusted for variables like hypertension with which OSA interact, the HR was still significant and more than that due to conventional risk factors (1.97 against 1.09 for hypertension, 1.31 for diabetics and 1.46 for smoking). (Table 4) . A trend analysis for the relationship between the severity of OSA and composite outcome of stroke or death from any cause showed that as AHI increases so does the hazards ratio, with patients with AHI > 36 having a hazards ratio of 3.3 (1.74-6.26, 95% CI) ( Table 4) . 24 This corroborates the cross sectional results of Sleep Heart Health study, a population based cohort study involving 6424 individuals, showing that the prevalence of stroke, coronary heart disease, hypertension and congestive cardiac failure increases with the severity of OSA as determined by AHI increases. 25 More recently, in a prospective study on 392 patients with coronary artery disease, 34 % patients had an AHI > 5 , among which 12% (47 patients) developed stroke, with the HR for stroke being 2.89 (1.37 -6.09). 26 Martin et al in an observational study involving 1651 individuals in 5 arms (healthy adults, simple snorers, untreated mild-moderate OSA, untreated severe OSA and severe OSA treated with CPAP) with a mean follow up of 10 years found patients with untreated severe OSA have about 3 times greater incidence of getting fatal and nonfatal cardiovascular events, while the risk of fatal end-points was comparable in simple snorers, patients with untreated (Table 4) . 27 
OSA as a risk factor for hypertension
Peppard et al in a prospective population based studythe Wisconsin sleep cohort study-involving 709 participants in 4 years follow up and 184 participants in 8 years follow up, found that the odds ratio for hypertension in patients with AHI > 15 (i.e. moderatesevere OSA as per AASM task force criteria 1 ) adjusted for baseline hypertension status was 4.54, while that adjusted for age and sex in addition to baseline hypertension status was 4.47. When the anthropometric parameters of BMI and waist and neck circumference were adjusted to the model the OD was 2.89, whereas with sequential adjustment for alcohol and cigarette use the OD did not change from the value of 2.89. Here again there is a progressive increase in risk with increase in AHI. 28 The adjustment for BMI and waist circumference may not be entirely justifiable as it undermines the cumulative risk of OSA as OSA itself has been found to be a risk factor for the metabolic syndrome, of which increased BMI and waist circumference are components. 29, 30 Similarly, one might undermine the role of OSA as a risk factor for stroke, if adjustment is made for hypertension, since OSA, as observed by Peppard et al, raises the risk for hypertension by 3-4 times. Alajmi et al in a meta-analysis of randomized control trials on the effect of CPAP therapy on blood pressure in patients with OSA, concluded that CPAP is not useful in reducing BP in unselected patients with OSA. However, in patients with severe OSA ( AHI > 30), there was a definite trend towards greater BP reduction ( Table 5) . 29 Logan et al has reported that in patients whose hypertension was refractory to medical therapy, 87% had OSA. 30 The same group has reported a BP reduction to the tune of 10mmHg in patients with refractory hypertension treated with CPAP. 31 As with the results of treatment trial of Martin et al, 27 the effect of treatment of OSA is significant mainly in those with severe disease and studies which did not apply such a selection, did not show any treatment benefit. Also, treatment effect was apparent in studies where the proportion of patients with baseline hypertension was more, while studies on normotensive population, the BP lowering effect of CPAP therapy was not evident. Another recurring issue is that of compliance to CPAP therapy. Only studies which reported mean duration of 5 hours/night of CPAP compliance showed any demonstrable reduction in BP.
Recognizing the importance of sleep-disordered breathing in cerebrovascular disease -an update
Another interesting feature of blood pressure profile in patients with OSA is that they do not show the normal 15-20% fall in blood pressure (nocturnal dipping of BP) seen during sleep. Loredo et al have reported that 85% of patients with OSA were 'non-dippers'. 32 Suzuki et al observe that non dippers are at increased risk for cerebrovascular events, cardiac arrhythmias and cardiac hypertrophy.
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Treatment trials evaluating vascular outcome
Buchner et al in a prospective control trial of CPAP therapy in mild-moderate OSA involving 288 patients (209 in treatment arm and 79 in control arm) with fatal and nonfatal vascular events (stroke, acute coronary syndrome) as outcome measures found that 80.3% of patients in the treatment arm have event free survival at 10 yrs, while the same was 51.8% in the control arm (p< 0.001). 34 In the partly retrospective study by Doherty et al patients with AHI > 15/Hr was offered CPAP therapy. Patients who were compliant on CPAP were compared with those who were noncompliant on CPAP for death due to vascular events in a 5 years follow up period. There was a significant excess of cardiovascular deaths (nine deaths [14. 8%] vs two deaths [1.9%], respectively; p = 0.009) and a nonsignificant increase in cardiovascular morbidity in the untreated group compared to those in the CPAP group. Furthermore, the total number of cardiovascular events (death and new cardiovascular disease combined) was significantly greater in the untreated group compared to that in the CPAP group (31% vs 18%, respectively; p < 0.05). 35 Martinez-Garcia et al in their prospective control trial involving acute ischemic stroke patients, PSG was done 2 months after the ictus and patients with AHI 20 or more were offered CPAP.
Similar to Doherty's study, patients tolerant on CPAP was taken as the treatment group (n:15, 29.4%), while those intolerant on CPAP (n: 36) was followed up as the control and assessed for new vascular events during a 18 months follow up period. Patients on CPAP had 1 vascular event (6.7%), while the 'control' arm had Garima Shukla, PR Srijithesh (Table 6 ).
There are several concerns regarding the design and methodology of these studies. Apart from the fact that they are nonrandomized, the inclusion criteria for the control group was the highly questionable criteria of 'intolerance' to CPAP and the treatment and control groups were asymmetrical. However, in the context of a host of evidences showing the significance of OSA as a vascular risk, and given the magnitude of the effect size (absolute risk reduction and number needed to treat in the studies by Buchner et al and Martinez-Garcia et al being 28.5% and 3.5 and 28.3% & 3.4 respectively), these outcomes should not be ignored. Moreover, it is almost impossible to conduct a placebo controlled RCT with a follow up long enough to demonstrate vascular outcomes with a device as CPAP. The use of sham CPAP or subtherpaeutic CPAP for prolonged period is not feasible, and unethical.
Conclusion
To conclude, there is overwhelming clinical and experimental evidence implicating sleep-disordered breathing, in particular obstructive sleep apnea as a risk factor of stroke. However, treatment trials with CPAP are limited by methodological issues and the issue of compliance, preventing clear-cut evidence-based treatment recommendation. In clinical practice, it therefore important to evaluate for SDB as a reversible risk factor of stroke and refractory hypertension on an individual basis, and offer the option of appropriate therapy, especially in cases of moderate-to-severe OSA, keeping in mind that the most important limitation in the current treatment options is the issue of compliance.
